Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390083 | 0.91 | HRH3 (0.45) | HRH3ACHE | |
| SCHEMBL3387524 | 0.88 | GRIN2D (0.48) | EHMT2EHMT1HRH3KDM4EALDH1A1 | |
| SCHEMBL3388275 | 0.86 | HRH3 (0.39) | EHMT2EHMT1HRH3ACHE | |
| SCHEMBL3386811 | 0.85 | ELOVL1 (0.42) | EHMT2EHMT1HRH3ACHE | |
| SCHEMBL3389318 | 0.84 | BACE1 (0.42) | HRH3KDM4EACHE | |
| SCHEMBL3389354 | 0.83 | GRIN2D (0.47) | HRH3SLC6A4 | |
| SCHEMBL3389947 | 0.82 | HRH3 (0.42) | HRH3ALDH1A1KMT2A | |
| SCHEMBL3389303 | 0.82 | GRIN2D (0.46) | HRH3SLC6A4ACHE | |
| SCHEMBL3384833 | 0.82 | HRH3 (0.44) | HRH3ACHE | |
| SCHEMBL3388532 | 0.81 | HRH3 (0.44) | HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | claimed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | claimed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | claimed |
| EP-1756104-B1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | EHMT2 261/4885EHMT1 195/4885HRH3 2/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | EHMT2 261/4885EHMT1 195/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.